The price-to-earnings ratio for Black Diamond Therapeutics Inc (NASDAQ: BDTX) is above average at 28.69x, Company’s 36-month beta value is 2.63.Analysts have differing opinions on the stock, with 3 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for BDTX is 43.15M, and currently, short sellers hold a 21.87% ratio of that floaft. The average trading volume of BDTX on May 13, 2025 was 3.29M shares.
BDTX) stock’s latest price update
Black Diamond Therapeutics Inc (NASDAQ: BDTX)’s stock price has gone rise by 0.48 in comparison to its previous close of 1.75, however, the company has experienced a 20.03% increase in its stock price over the last five trading days. globenewswire.com reported 2025-05-12 that CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) — Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today reported financial results for the first quarter ended March 31, 2025, and provided a corporate update.
BDTX’s Market Performance
BDTX’s stock has risen by 20.03% in the past week, with a monthly rise of 26.50% and a quarterly drop of -19.34%. The volatility ratio for the week is 9.40% while the volatility levels for the last 30 days are 7.97% for Black Diamond Therapeutics Inc The simple moving average for the past 20 days is 10.06% for BDTX’s stock, with a -41.97% simple moving average for the past 200 days.
Analysts’ Opinion of BDTX
Many brokerage firms have already submitted their reports for BDTX stocks, with Raymond James repeating the rating for BDTX by listing it as a “Outperform.” The predicted price for BDTX in the upcoming period, according to Raymond James is $20 based on the research report published on July 31, 2024 of the previous year 2024.
Stifel gave a rating of “Buy” to BDTX, setting the target price at $10 in the report published on June 30th of the previous year.
BDTX Trading at 8.94% from the 50-Day Moving Average
After a stumble in the market that brought BDTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -73.95% of loss for the given period.
Volatility was left at 7.97%, however, over the last 30 days, the volatility rate increased by 9.40%, as shares surge +28.57% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -5.76% lower at present.
During the last 5 trading sessions, BDTX rose by +22.45%, which changed the moving average for the period of 200-days by -71.11% in comparison to the 20-day moving average, which settled at $1.6000. In addition, Black Diamond Therapeutics Inc saw -17.83% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BDTX starting from BIOTECH GROWTH N V, who sale 5,784,292 shares at the price of $2.07 back on Mar 19 ’25. After this action, BIOTECH GROWTH N V now owns 2,733,547 shares of Black Diamond Therapeutics Inc, valued at $11,997,749 using the latest closing price.
Versant Venture Capital VI, L., the 10% Owner of Black Diamond Therapeutics Inc, sale 221,600 shares at $6.32 during a trade that took place back on Aug 28 ’24, which means that Versant Venture Capital VI, L. is holding 3,726,341 shares at $1,400,556 based on the most recent closing price.
Stock Fundamentals for BDTX
The total capital return value is set at -0.77. Equity return is now at value 4.14, with 3.19 for asset returns.
Based on Black Diamond Therapeutics Inc (BDTX), the company’s capital structure generated 0.21 points at debt to capital in total, while cash flow to debt ratio is standing at -2.81.
Currently, EBITDA for the company is -69.33 million with net debt to EBITDA at 0.18. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.92.
Conclusion
In a nutshell, Black Diamond Therapeutics Inc (BDTX) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
